X-376

본문 바로가기


Home > Product > X-376
Selling leads
X-376
Posting date : Jun 30, 2025
Membership
Free Member Scince Jun 27, 2025
FOB Price
detailed discussion
Min. Order Quantity
1
Supply Abillity
hundreds of kgs
Port
Shanghai Port
Payment Terms
detailed discussion
Package
Convenient package
Keyword :
Category
Contact
Lena
Selling Leads Detail
Company Info
 
Quick Detail
Place of Origin
China [CN]
Brand Name
Royal
Model Number
+86 15242851296
HS-CODE
-
Package & Delivery Lead Time
Package
Convenient package
Detailed Description

The second-generation ALK inhibitor enxatinib (X-396) is comprehensively superior to the first-generation crizotinib. Global multi-center Phase 3 clinical trials began in June 2016, and the approval for multi-center domestic phase 3 clinical trials was granted in June 2017. Both are first-line drugs and are expected to be available for sale from 2019 to 2021. It is estimated that the global sales of Chemicalbooks will reach the 500 million US dollar level, including 300 million US dollars overseas and 1.2 billion US dollars domestically. In addition, X-396 initiated a Phase 2 clinical study of "ALK-positive advanced malignant melanoma" in the United States in December 2017. It is the world's first clinical study of ALK inhibitors for the treatment of melanoma and is expected to be approved for marketing as an "orphan drug".


ECROBOT CO., Ltd, Business Registration Number : 220-88-71747, CEO J.W.Park, TEL : +82-2-552-7676, E-mail : E-mail : Contact us
Address : (Hwanghwa B/D 11F, Yeoksam-dong)320, Gangnam-daero, Gangnam-gu, Seoul, South Korea
About Us Privacy Policy Terms of use Copyright © 2000-2026 ECROBOT.COM. All rights reserved.
Top